Next Article in Journal / Special Issue
Understanding the Osteosarcoma Pathobiology: A Comparative Oncology Approach
Previous Article in Journal / Special Issue
Canine Mammary Carcinomas: A Comparative Analysis of Altered Gene Expression

Canine Histiocytic Malignancies—Challenges and Opportunities

Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27607, USA
Comparative Medicine Institute, North Carolina State University, Raleigh, NC 27607, USA
Center for Human Health and the Environment, North Carolina State University, Raleigh, NC 27607, USA
Cancer Genetics Program, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA
Author to whom correspondence should be addressed.
Academic Editor: Jaime F. Modiano
Vet. Sci. 2016, 3(1), 2;
Received: 15 November 2015 / Revised: 4 December 2015 / Accepted: 14 December 2015 / Published: 4 January 2016
(This article belongs to the Special Issue Comparative Pathogenesis of Cancers in Animals and Humans)
Canine histiocytic malignancies (HM) are aggressive tumors that occur with particularly high frequency in certain breeds including Bernese mountain dogs and flat-coated retrievers. Robust diagnosis of HM commonly utilizes immunohistochemical stains that are broadly ineffective on formalin-fixed tissues; thus the diagnosis is often one of exclusion. Clinical outcomes are generally poor, with frequent metastasis and therapeutic failure lowering overall survival at time of diagnosis to an average of less than two months in the majority of published work. The limited understanding of the molecular mechanisms underlying HM has hindered the development of more effective diagnostic modalities and the identification of therapeutic targets. A potential avenue exists for advancing clinical management of canine cancers through extrapolation from a close counterpart in human medicine. Historically, HM have been compared to the rare and understudied subset of human cancers involving the dendritic lineage, such as dendritic cell sarcoma or Langerhans cell sarcoma. Recent data have now thrown into question the cellular origin of HM, suggesting that the disease may originate from the macrophage lineage. This review summarizes existing knowledge of HM from the clinical, histologic and molecular perspectives, and highlights avenues for future research that may aid the development of novel diagnostic and therapeutic approaches. In turn, a more advanced appreciation of the mechanisms underlying HM should clarify their cellular origin and identify appropriate opportunities for synergistic extrapolation between related canine and human cancers. View Full-Text
Keywords: cancer; sarcoma; macrophage; dendritic; disseminated cancer; sarcoma; macrophage; dendritic; disseminated
MDPI and ACS Style

Kennedy, K.; Thomas, R.; Breen, M. Canine Histiocytic Malignancies—Challenges and Opportunities. Vet. Sci. 2016, 3, 2.

AMA Style

Kennedy K, Thomas R, Breen M. Canine Histiocytic Malignancies—Challenges and Opportunities. Veterinary Sciences. 2016; 3(1):2.

Chicago/Turabian Style

Kennedy, Katherine, Rachael Thomas, and Matthew Breen. 2016. "Canine Histiocytic Malignancies—Challenges and Opportunities" Veterinary Sciences 3, no. 1: 2.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop